Annual report pursuant to Section 13 and 15(d)

Note 15 - Income Taxes (Tables)

v3.21.1
Note 15 - Income Taxes (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
   
As of December 31,
 
   
2020
   
2019
 
Deferred tax assets:
               
Net operating loss carryforwards
  $
34,365,098
    $
31,966,658
 
R&D credit carryforwards
   
9,301,709
     
9,150,580
 
AMT credit carryforward
   
     
310,620
 
Stock compensation
   
419,654
     
382,016
 
Intangibles
   
616,926
     
610,783
 
Disallowed interest expense
   
852,338
     
857,648
 
Temporary differences
   
267,312
     
333,728
 
Deferred tax assets before valuation allowance
   
45,823,037
     
43,612,033
 
Valuation allowance
   
(45,823,037
)
   
(43,301,413
)
Net deferred tax assets
  $
    $
310,620
 
Summary of Tax Credit Carryforwards [Table Text Block]
   
 
 
 
As of December 31, 2020
 
Generated
 
Expiration
   
U.S. Net
Operating
Loss
Carryforwards
   
U.S. R&D
Credit
Carryforwards
 
2001
 
2021
    $
    $
39,128
 
2002
 
2022
     
     
5,350
 
2003
 
2023
     
     
2,905
 
2004
 
2024
     
     
22,861
 
2005
 
2025
     
     
218,332
 
2006
 
2026
     
     
365,541
 
2007
 
2027
     
     
342,898
 
2008
 
2028
     
     
531,539
 
2009
 
2029
     
     
596,843
 
2010
 
2030
     
     
1,094,449
 
2011
 
2031
     
     
1,950,744
 
2012
 
2032
     
18,898,490
     
468,008
 
2013
 
2033
     
37,450,522
     
681,772
 
2014
 
2034
     
34,088,874
     
816,116
 
2015
 
2035
     
25,073,846
     
492,732
 
2016
 
2036
     
15,581,209
     
262,257
 
2017
 
2037
     
     
387,892
 
2018
 
2038
     
     
197,547
 
2019
 
N/A
     
11,245,808
     
213,065
 
2020
 
N/A
     
11,006,921
     
222,842
 
Total carryforwards
    $
153,345,670
    $
8,912,821
 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
   
2020
   
2019
 
   
Amount
   
%
   
Amount
   
%
 
Benefit at statutory rate
  $
(2,390,972
)
   
(21.0
)%
  $
(2,299,122
)
   
(21.0
)%
Adjustments to valuation allowance
   
2,521,625
     
22.1
%
   
2,355,947
     
15.3
%
Adjustments to R&D credit carryforwards
   
(151,129
)
   
(1.3
)%
   
(82,706
)
   
6.1
%
Permanent items and other
   
20,476
     
0.2
%
   
26,588
     
0.3
%
Provision (benefit) per financial statements
  $
     
 
    $
707